The association between maternal gestational diabetes (GDM) and manifestations of metabolic syndrome among Caucasian adolescents was studied with data from the population-based Northern Finland 1986 Birth Cohort. This is a longitudinal cohort study from early pregnancy until offspring age 16 years and includes data from a risk group-based GDM screen of pregnant mothers by an oral glucose tolerance test. Metabolic outcomes were compared between the offspring of women with GDM (OGDM; n ¼ 95) and reference group offspring (n ¼ 3,909). The prevalence of overweight was significantly higher in the OGDM group (18.8 vs. 8.4%; P < 0.001) than in the reference group. The median body mass index (20.8 vs. 20.2 kg/m 2 , 95% confidence interval (CI) for the percentage difference adjusted for sex: 3.5%, 9.5%), waist circumference (73.3 vs. 71.5 cm, 95% CI: 3.2%, 7.5%), and fasting insulin (10.20 vs. 9.30 milliunits/L, 95% CI: 5.9%, 26.0%) were higher, and homeostatic model assessmentinsulin sensitivity (74.7 vs. 82.3, 95% CI: À20.6%, À5.4%) was lower in the OGDM group. These differences were similar after an additional adjustment for birth weight and gestational age. The differences in waist circumference, insulin, and homeostatic model assessment-insulin sensitivity were attenuated but remained statistically significant after additional adjustment for body mass index at 16 years. These findings highlight the importance of prevention strategies among children born to women with GDM. adolescent; cohort studies; diabetes, gestational; metabolic syndrome X; phenotype; women Abbreviations: CI, confidence interval; GDM, maternal gestational diabetes; OGDM, offspring of women with GDM.
Overt maternal diabetes of both types 1 and 2 has been found to be associated with subsequent morbidity of the offspring (1) (2) (3) (4) (5) , but data are far fewer and more inconsistent concerning the role of transient deviant glucose metabolism, such as maternal gestational diabetes (GDM), for metabolic disorders among the offspring (6) (7) (8) (9) (10) (11) . The etiology of GDM is heterogeneous (12) , one well-known predisposing factor for GDM being obesity. As the prevalence of overweight is rapidly increasing in the population, an increase in glucose metabolism disorders during pregnancy is also expected.
Most previous studies on maternal diabetes and health of the offspring have been carried out in high-risk ethnic populations such as Pima Indians (3) , and rarely have the different types or timing of maternal diabetes been taken into account. Only 2 studies in a low-risk GDM population have been reported (6, 8) . Malcolm et al. (8) suggested that there is an increased risk of impaired glucose tolerance and overweight in the offspring of women with GDM (OGDM), while Boney et al. (6) reported that especially large-forgestational-age children of GDM mothers were at increased risk of so-called metabolic syndrome. However, these studies failed to compare risks with those of a control population (8) and had a high drop-out rate or restricted sample representation (6) . The use of the term ''metabolic syndrome'' has been debated and, until recently, no internationally accepted definition has been available (13, 14) . In the present study, we use the term metabolic syndrome as an overarching description of the condition of several adverse metabolic phenotypes clustering together (13) .
The development of features of metabolic syndrome may start much earlier in life than previously supposed and may be affected by both pre-and postnatal environmental and genetic variations and their interactions. To delay or prevent the development of overt disease, it is essential to identify groups at risk of metabolic disorders before clinical manifestations of disease. We report here the associations between GDM and metabolic syndrome (15) and its individual phenotypes (both as binary and continuous outcomes) in adolescent offspring, and we evaluate whether these associations are mediated/modified by factors such as gestational age, birth weight, and current body size. The critical questions are whether any increased risk of metabolic disorders among the offspring can be explained by overweight per se and whether other factors-independent of body mass index-are involved.
MATERIALS AND METHODS

Data collection
The prospective Northern Finland 1986 Birth Cohort is a general population-based sample with expected birth between July 1, 1985, and June 30, 1986 , comprising offspring from 9,247 singleton pregnancies followed since the 12th gestational week (99% coverage) (16, 17) . A clinical examination of the offspring was conducted at age 16 years in 2001-2002 with 75% participation. The ethical committee of the University of Oulu approved this study.
Screening of GDM
In Finland, free-of-charge health care is offered to pregnant women in municipal maternity welfare clinics with nearly 100% attendance. Screening for GDM by oral glucose tolerance test was performed in the clinics, according to national guidelines, at between 26 and 28 gestational weeks. Indications for screening were glucosuria, prior GDM, suspected fetal macrosomia, previous macrosomic infant (birth weight >4,500 g), maternal prepregnancy body mass index greater than 25 kg/m 2 , and age greater than 40 years. The oral glucose tolerance test was performed after overnight fasting by using a 75-g oral glucose load; the upper ranges of the normal venous blood glucose values were 5.5, 11.0, and 8.0 mmol/L at fasting, 1 hour, and 2 hours after initial load, respectively (national guidelines). In this study, a diagnosis of GDM was made if there was 1 or more abnormal value in the oral glucose tolerance test.
Study groups
The allocation of mothers/offspring into the study groups is described in Figure 1 . The oral glucose tolerance test was performed in 1,228 mothers. GDM was diagnosed in 139 cases, of which 12 were treated with insulin and 17 with (18) , was measured at the level midway between the lowest rib margin and the iliac crest. Systolic and diastolic blood pressures were measured in the sitting position after 15 minutes' rest with the cuff on the right upper arm, by trained nurses using a standardized procedure and ongoing quality control. An Omron 705CP oscillometric pressure meter (Omron Corporation, Shiokoji Horikawa, Kyoto, Japan), or mercury sphygmomanometer if this failed, was used. Two readings were taken 2 minutes apart, and the average of the 2 measurements was used. Mean arterial pressure (MAP) was calculated by the formula, MAP ¼ (SBP þ (2 3 DBP))/3, where SBP refers to systolic blood pressure and DBP refers to diastolic blood pressure.
Blood samples and laboratory methods
The blood samples were drawn after overnight fasting (8.00-11.00 AM). Samples for serum insulin were stored at À20°C until analyzed by radioimmunoassay with commercial reagents (Pharmacia Diagnostics, Uppsala, Sweden) within 7 days. The other samples were analyzed within 24 hours of sampling in the Oulu University Hospital laboratory by using ongoing internal/external quality control. Plasma glucose, serum total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and triglycerides were analyzed by a Cobas Integra 700 automatic analyzer (Roche Diagnostics, Basel, Switzerland). Paired fasting glucose and insulin levels were used to generate measures of insulin sensitivity by using the homeostatic model assessment method (19) , a valid approach for insulin sensitivity in normal weight prepubertal and pubertal nondiabetic children (20) .
Definition of metabolic syndrome
We used the International Diabetes Federation adult definition for metabolic syndrome, because it is recommended for adolescents 16 years of age or older (21, 22) , and it covers body mass index contrary to the pediatric definition. The adult definition gives, however, a slightly lower prevalence of metabolic syndrome than does the pediatric definition (23) . According to the adult definition, the diagnosis of metabolic syndrome requires central obesity as assessed by waist circumference (!94 cm in men; !80 cm in women) or body mass index (!30 kg/m 2 ) and 2 of the following 4 criteria to be fulfilled: 1) raised triglycerides (>1.7 mmol/L or specific treatment for this lipid abnormality), 2) reduced high density lipoprotein cholesterol (<1.03 mmol/L in men; <1.29 mmol/L in women; or specific treatment for this lipid abnormality), 3) raised blood pressure (systolic !130 mm Hg or diastolic !85 mm Hg or treatment of previously diagnosed hypertension), and 4) raised fasting plasma glucose (!5.6 mmol/L or previously diagnosed type 2 diabetes).
Statistical methods
The continuous outcome variables are reported as medians with interquartile ranges, and comparisons between groups are reported as percentage differences (95% confidence intervals) because of logarithmic transformations of the outcomes. The analyses were conducted for all adolescents and stratified by sex. There were no significant interactions between GDM and sex; consequently, the main results are presented sex adjusted. We report the results from multiple linear regression adjusted for the following: 1) sex only; 2) sex, birth weight, and gestational age; 3) sex and body mass index at age 16 years; and 4) all of the above. Adjustments for gestational age and birth weight by sex are shown in Web Table 1 . (This information is posted on the Journal's website (http://aje.oxfordjournals.org/).) Birth weight and gestational age are in these analyses intervening variables and, by adjusting for them, we explored the extent of differences in metabolic factors that were not fully explained by them. Socioeconomic status did not modify the associations (data not shown). Student's t or chi-squared tests were used as appropriate. For the analysis of metabolic syndrome and its binary components, we used logistic regression and report results as odds ratios with their 95% confidence intervals. These analyses were conducted for all adolescents and were adjusted for 1) sex only and 2) sex, birth weight, and gestational age. We used SAS/STAT, version 9.1, software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Compared with the reference group, mothers with GDM were older, heavier, and more often multiparous, and their infants had a shorter gestational age and higher birth weight ( Table 1) .
The prevalence of overweight (body mass index >25 kg/m 2 ) was significantly higher in the OGDM than in the reference group (18.8% vs. 8.4%; P < 0.001), as were the median body mass index (20.8 kg/m 2 vs. 20.2 kg/m 2 , 95% confidence interval (CI) for the percentage difference adjusted for sex: 3.5%, 9.5%) and waist circumference (73.3 cm vs. 71.5 cm, 95% CI: 3.2%, 7.5%) ( Table 2) . Moreover, in the OGDM group, fasting insulin was higher, and homeostatic model assessment-insulin sensitivity was lower than in the reference group; the differences were similar after additional adjustment for birth weight and gestational age. Although the adjustment for only sex and current body mass index at 16 years attenuated the differences between the groups, the estimates for waist circumference, fasting insulin, and homeostatic model assessment-insulin sensitivity remained statistically significant. With a few exceptions, simultaneous adjustment for all intervening factors generally strengthened the differences between the OGDM and reference groups compared with the sex-and body mass indexadjusted model ( Table 2 ).
The OGDM group had a higher systolic blood pressure compared with the reference group (unadjusted percentage difference ¼ 2.5%, 95% CI: 0.3%, 4.8%) but not significantly after adjustment for sex. There were no statistically significant differences in the lipid profile between the groups ( Table 2) .
The medians of body mass index and waist circumference were higher in the OGDM group than in the reference group when the results were stratified by sex. Differences in insulin resistance (lower homeostatic model assessmentinsulin sensitivity, higher fasting insulin) were more clearly seen among female OGDM compared with males, but a formal test did not show statistically significant sex interaction (Web Table 1 ).
The mother's gestational diabetes raised the odds of having metabolic syndrome (adjusted odds ratio ¼ 3.53, 95% CI: 1.33, 9.31) ( Table 3 ). As we studied each component of metabolic syndrome separately, we observed no statistically significant differences in the levels of triglycerides, high density lipoprotein cholesterol, and blood pressure between the OGDM group and the reference group. More adolescents in the OGDM group than in the reference group exceeded the cutoff for fasting plasma glucose (23.6% vs. 15.3%), and the adjusted odds of 1.63 (95% CI: 0.97, 2.74) almost reached significance. The most striking differences were seen in central obesity with 17.0% being centrally obese as assessed by waist circumference in the OGDM group compared with 7.1% in the reference group (for assessment by body mass index: 6.4% vs. 1.9%). The corresponding adjusted odds ratios were 2.71 (95% CI: 1.52, 4.82) for waist assessment and 3.10 (95% CI: 1.28, 7.52) for body mass index assessment.
DISCUSSION
In our prospective general population study, offspring of mothers with GDM had markers of insulin resistance and metabolic syndrome by adolescence, independently of birth weight, preterm birth, or later overweight. Alarmingly, a significant proportion of the adolescents already fulfill the criteria for metabolic syndrome, especially those born to the mothers with GDM. This may lead to a rapid increase in metabolic diseases, especially type 2 diabetes, in adulthood.
Disturbances of metabolic parameters in offspring after exposure to maternal diabetes in utero have been found in some studies (1-4, 6 ), but not all (7) . As far as we know, only 3 prospective cohort studies have evaluated the association between GDM and intermediate markers of metabolic disease in the offspring (6, 8, 24) . However, there were large age differences between the offspring groups, as well as high drop-out rates, and they were mainly retrospective (7), based on self-reporting (11), or failed to distinguish between different types of diabetes (4, 24) . In contrast, in our study, all the children were of the same age at the outcome survey, minimizing the effect of variation in puberty stage. All were European, born in the same area during the same time period, and similarly followed up. The high retention rate, 75%-99% through the years, makes this cohort the most comprehensive long-term follow-up of offspring exposed to GDM in a general population to date. Data collection was prospective with validated methods including scrutiny of hospital records to confirm diagnoses of GDM. We therefore believe that the subgroups in the study are reliably allocated. Detailed case assessment additionally showed that the oral glucose tolerance test was not conducted according to current guidelines among all women at risk for GDM, even in the well-respected Finnish maternity care system; overweight was the most often overlooked indication for the oral glucose tolerance test. To avoid misclassification, we excluded those women and their offspring from the analyses, which may have introduced some selection bias. The control group included the women who did not have any specific risk factors for GDM and, therefore, were not oral glucose tolerance test screened. Consequently, it is possible that some of them may have developed GDM, which can dilute the associations between the groups. In spite of that, the differences in metabolic outcomes between the exposed and the unexposed were quite striking.
The association between GDM and metabolic disturbance of offspring is likely to be multifactorial, including genetic and shared pre-and postnatal environmental factors and their interactions. In spite of intensive research, we do not know exactly how genes and the environment contribute to the observed association over the life course. For example, recently, Shaat et al. (12) associated a variant in the transcription factor 7-like 2 gene (TCF7L2) with increased risk of GDM, while we showed that the same variant associated with birth weight in offspring but that this was predominantly an effect mediated by maternal genotype, resulting in deficient glycemic control during pregnancy and higher birth weight (25) . We showed in the present study that associations between GDM and the metabolic outcomes were independent of birth weight and gestational age, suggesting that other mechanisms than excessive growth may be involved. Elevated insulin concentrations during critical periods of fetal development may also contribute via incompletely understood mechanisms to a malprogramming of neuroendocrine systems that regulate later weight gain and metabolism (26) . Intrauterine predisposition to maternal diabetes may further lead to the lack of acute insulin response in the offspring irrespective of obesity or insulin resistance (5, 27) . This illustrates how complex the relations are between maternal and fetal genotypes and intrauterine environment in influencing a child's health. In a current study, a lack of genetic data and a low number of adolescents whose parents had so far developed type 2 diabetes precluded further distinguishing of the roles of genes and environment (28) . Because GDM was diagnosed after 1 abnormal oral glucose tolerance test value, the screen-positive group includes mothers with a mild metabolic disturbance. Despite this, differences in metabolic parameters between the 2 offspring groups were apparent and of a size to be of potential clinical significance for future risk of metabolic disease. These findings further emphasize the importance of the in utero environment, whatever the mechanisms are, in the development and potential prevention of metabolic disturbances. The results support previous, mostly smaller scale reports, in which even impaired maternal glucose tolerance under the threshold for overt diabetes was associated with increased risk of metabolic disturbance in the offspring (29, 30) . On the basis of our study and previous studies, we can speculate that the classic Pedersen hypothesis (31) might be extended into later life by hypothesizing that maternal hyperglycemia leads not only to fetal hyperinsulinemia and macrosomia but also to obesity and insulin resistance in adolescence.
Adolescence is a critical period for the development of adiposity (10) , and increased body mass index at or around puberty increases the risk of adult obesity (32, 33) . We used waist circumference, serum insulin levels, and homeostatic model assessment-insulin sensitivity as the main indicators of adiposity and insulin resistance. Waist circumference was significantly higher in OGDM after adjustment for current body mass index, indicating increased visceral adiposity. The limitation of the study was that we could not investigate the effect(s) of potential modifying factors, such as breastfeeding, diet of the offspring during the life course, or current weight of the parents, on the development of adiposity or other adverse metabolic outcomes. It is probable that offspring adapt dietary and physical activity behaviors similar to those of their obese parents, potentially leading to adverse metabolic traits. With modification of families' lifestyle factors, it may be possible at least to delay the onset of type 2 diabetes in people at risk (34) . Even slight differences in body mass index are associated with large differences in the prevalence of metabolic disorders (21) . These findings underscore the importance of identifying at-risk groups early enough to initiate guidance on lifestyle factors in order to avoid future development of metabolic syndrome and related sequelae.
Previous studies suggest that disturbances in glucose metabolism may differ between genders (22, 35), but there are no studies related to offspring exposure to GDM. In our study, measures of insulin resistance were more pronounced among female than male OGDM, although formal interaction tests were nonsignificant.
As a conclusion, we demonstrated that the metabolic syndrome and adverse metabolic phenotypes are already apparent in the adolescent offspring of GDM mothers. The associations were not modified by birth weight or gestational age and existed even after adjustment for current body mass. The indisputable strength of our analysis is the emphasis on metabolic phenotypes rather than on only metabolic syndrome. Planning preventive and therapeutic strategies for this at-risk group should be considered before the development of clinical manifestations of metabolic syndrome. Unraveling the role of genetic factors, abnormal fetal metabolic milieu, and environmental factors in postnatal life in increasing risk of metabolic disturbance will require ongoing longitudinal research into young adulthood and beyond. 
